Navigation Links
Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
Date:7/23/2008

t Duska has a clear plan to acquire all the data that would be necessary to support the filing of a NDA for ATPace(TM) under Section 505(b)(2), and the expectation that the SPA by the FDA will facilitate the completion of the clinical development of ATPace(TM) in a timely fashion. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the FDA comments about the prospective clinical design may not be favorable, that further clinical studies may be required prior to filing the NDA, the anticipated SPA procedure may not be applied to the proposed protocol, the clinical trial for approval of ATPace(TM) may not be successful and that the NDA may be rejected. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Duska Therapeutics Obtains Standard & Poors Listing
2. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
3. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
4. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
7. Organizational Changes at Silence Therapeutics
8. Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
9. Arno Therapeutics Announces New Ticker Symbol
10. Lorus Therapeutics Receives $600 Thousand From Escrow Account
11. Silence Therapeutics Announces Successful Opposition of Glover Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014 Ophthalmic drug delivery ... and challenging endeavors as the anatomy, physiology and ... to the foreign substances. Ocular drug delivery technologies ... medication and minimal use of needles; also it ... and provides specific targeting within the ocular globe. ...
(Date:8/22/2014)... Los Angeles (PRWEB) August 22, 2014 ... for age-defying products, is in the spotlight again. ... night cream and its NeriumFirmTM Body Contouring Cream ... presented by Backstage Creations during the 66th Primetime ... the patented NAE-8® extract, third-party clinical trials show ...
(Date:8/21/2014)... Finnish-Swedish research group at the Institute for Molecular ... institutet, Stockholm, has developed a novel "man and ... This innovative diagnostic aid was described in ... The method is based on computer vision algorithms ... combined with visualization of only the diagnostically most ...
(Date:8/21/2014)... COLD SPRING, N.Y. , Aug. 21, 2014 ... today the launch of their Nutraceutical "TELO-20 for ... first and only Telomere-lengthening supplement in the world ... the ends of every chromosome in the body. ... the world,s leading experts in Telomere Science and ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3
... , , , ... SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical ... care of adults with Attention-Deficit/Hyperactivity Disorder (ADHD), a psychiatric behavioral ... country.* The first initiative, "RoADHD Trip," a multi-city self ...
... Aug. 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ... letter from the Listing Qualifications Department of The NASDAQ ... with Listing Rule 5550(a)(2). , We plan to request ... Panel") to review the NASDAQ,s determination of the continued ...
... Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) ... therapy and oncology, today reported Phase 3 results for ... trial Z-041 in benign prostatic hyperplasia (BPH), with its ... on March 6, 2009, sanofi-aventis U.S. LLC entered into ...
Cached Biology Technology:Shire Initiates Two Adult ADHD Outreach Programs 2Shire Initiates Two Adult ADHD Outreach Programs 3Shire Initiates Two Adult ADHD Outreach Programs 4Vasogen Receives NASDAQ Notification Related to Minimum Bid Price 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 5AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 6AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 7
(Date:8/21/2014)... they are the ultimate source of all organic matter ... on algae, too, to suck up climate-warming carbon dioxide ... of the ocean. Now, by using a combination of ... that viruses infecting those algae are driving the life-and-death ... stays essentially the same, and this has important implications ...
(Date:8/21/2014)... In a finding that has implications for life in ... in the solar system, LSU Associate Professor of Biological ... National Science Foundation, or NSF, this week published a ... lake that lies 800 meters (2600 feet) beneath the ... microbial ecosystems.", Given that more than 400 subglacial lakes ...
(Date:8/21/2014)... connectors, designed by an international standards process, will be ... to an invited review published in the OnlineFirst version ... ), the official journal of the American Society for ... greatly reduce the occurrence of misconnection that can be ... which are used to join medical devices, components, and ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4New feeding tube connectors will improve patient safety 2
... NARRAGANSETT, R.I. August 30, 2010 ... at the University of Rhode Island Graduate School ... Science Foundation (NSF) RAPID Response grant through the ... $199,909 NSF grant, Improving Communication of Oil Spill ...
... Undergrads often take communication courses unrelated to their major ... teamed up with the Library and English Departments to ... and understand literature searchers and incorporate them into papers ... and Gail R. Nonnecke, Iowa State University faculty from ...
... diseases are hereditary. But despite significant progress in genome ... The discovery of the underlying genetic defect is, however, ... of innovative approaches to their treatment. Scientists at the ... of Medical Genetics at the Charit Universittsmedizin - Berlin ...
Cached Biology News:Metcalf Institute wins NSF grant to help journalism and communication of oil spill research 2Teaching communication and information literacy skills 2All genes in 1 go 2
... The SlowFade Light Antifade Kit is ... photobleaching seen with fluorescent dyes. This formulation ... fluorescein AMCA and Cascade Blue fluorophores that ... (S-2828). This kit is available with the ...
Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
in vitro Translation, Accessory Products...
...
Biology Products: